221 related articles for article (PubMed ID: 31462218)
21. [Caspase-3 plays a required role in PC12 cell apoptotic death induced by roscovitine].
Gao JX; Zhou YQ; Zhang RH; Ma XL; Liu KJ
Sheng Li Xue Bao; 2005 Dec; 57(6):755-60. PubMed ID: 16344902
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Ishimaru T; Lau J; Jackson AL; Modiano JF; Weiss RH
J Urol; 2010 Nov; 184(5):2143-9. PubMed ID: 20850841
[TBL] [Abstract][Full Text] [Related]
23. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
24. Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199.
García CP; Videla Richardson GA; Dimopoulos NA; Fernandez Espinosa DD; Miriuka SG; Sevlever GE; Romorini L; Scassa ME
PLoS One; 2016; 11(3):e0152607. PubMed ID: 27030982
[TBL] [Abstract][Full Text] [Related]
25. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis.
Leitch AE; Riley NA; Sheldrake TA; Festa M; Fox S; Duffin R; Haslett C; Rossi AG
Eur J Immunol; 2010 Apr; 40(4):1127-38. PubMed ID: 20127676
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.
Garrofé-Ochoa X; Cosialls AM; Ribas J; Gil J; Boix J
Apoptosis; 2011 Jul; 16(7):660-70. PubMed ID: 21505869
[TBL] [Abstract][Full Text] [Related]
27. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.
Wojciechowski J; Horky M; Gueorguieva M; Węsierska-Gądek J
Int J Cancer; 2003 Sep; 106(4):486-495. PubMed ID: 12845642
[TBL] [Abstract][Full Text] [Related]
28. Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.
Węsierska-Gądek J; Hackl S; Zulehner N; Maurer M; Komina O
J Cell Biochem; 2011 Jan; 112(1):273-88. PubMed ID: 21080333
[TBL] [Abstract][Full Text] [Related]
29. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
[TBL] [Abstract][Full Text] [Related]
30. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
31. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
32. Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.
David-Pfeuty T; Legraverend M; Ludwig O; Grierson DS
Int J Oncol; 2010 Apr; 36(4):873-81. PubMed ID: 20198331
[TBL] [Abstract][Full Text] [Related]
33. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
[TBL] [Abstract][Full Text] [Related]
34. Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.
Komina O; Nosske E; Maurer M; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):27-35. PubMed ID: 21275263
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
36. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
[TBL] [Abstract][Full Text] [Related]
37. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
Wesierska-Gadek J; Wandl S; Kramer MP; Pickem C; Krystof V; Hajek SB
J Cell Biochem; 2008 Dec; 105(5):1161-71. PubMed ID: 18846503
[TBL] [Abstract][Full Text] [Related]
38. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
[TBL] [Abstract][Full Text] [Related]
39. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Rogalińska M; Błoński JZ; Komina O; Góralski P; Zołnierczyk JD; Piekarski H; Robak T; Kiliańska ZM; Wesierska-Gadek J
J Cell Biochem; 2010 Jan; 109(1):217-35. PubMed ID: 19911397
[TBL] [Abstract][Full Text] [Related]
40. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
